Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).

Exclusion Criteria

• •Patients feasible for curative treatment (e.g. resection or local ablation)
• •Previous TACE or SIRT
• •Prior Chemotherapy
• •Child Pugh stage C
• •ECOG Performance Status \>1
• •Tumor involvement \>50% of the liver
• •Extrahepatic tumor
• •Serum Bilirubin \>2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine \>2 mg/dl; Leukocytes \<3000/ml; Thrombocytes \<50000/ml
• •Esophageal bleeding during the last 3 months
• •Hepatic encephalopathy
• •Transjugular intrahepatic portosystemic shunt (TIPS)
• •Infiltration or occlusion of the main portal vein
• •Hepatofugal blood flow in the portal vein
• •Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan (MAA-scan)
• •Contraindications against angiography
• •Pregnancy